Health Care • Biotechnology: Pharmaceutical Preparations
$1.42 ▼ -0.08
(-5.67%)
MKT CAP: $5.2M • VOL: 5.9K
52W L $1 52W H $5
ROARABLE / RQD
D- • 36/100
PIOTROSKI
2 / 9
PULM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $7.8M | $7.3M |
| YoY Revenue Growth % | — | +7.0% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$5.2M | -$9.8M | -$14.7M |
| Operating Margin % | — | -80.0% | -80.0% |
| Net Income (GAAP) | -$5.2M | -$9.6M | -$14.1M |
| EBITDA (Normalized) | — | -$9.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.4M | -$10.7M | -$16.0M |
| Capital Expenditures (CapEx) | — | $398.0K | — |
| Free Cash Flow (FCF) | -$5.4M | -$11.1M | -$16.0M |
| FCF Margin % | — | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $4.1M | $9.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $3.8M | $8.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PULM.